FINASTERIDE 0.25% + MINOXIDIL 5%

FINASTERIDE 0.25% + MINOXIDIL 5%

€0,00
Skip to product information
FINASTERIDE 0.25% + MINOXIDIL 5%
Research Formulation • Topical Delivery System

FINASTERIDE 0.25% / MINOXIDIL 5%

Topical Research Solution
CAS No. Finasteride: 98319-26-7 / Minoxidil: 38304-91-5
Format 0.25% w/v Finasteride + 5% w/v Minoxidil
Volume 50 mL
Access request-only

Dual-compound, solvent-based topical research formulation developed for localized, non-clinical 5α-reductase pathway and follicular response research studies.

Submit Formulation Request

Prefer email communication?
Request this formulation via our consultation form.

Request-only supply. No instant checkout. All formulation requests are reviewed before fulfilment.

Technical Data
Chemical Identification
Chemical NameFinasteride / Minoxidil dual-compound topical research formulation
SynonymsFinasteride
Minoxidil
Dual-compound topical research formulation
Molecular FormulaFinasteride: C23H36N2O2 / Minoxidil: C9H15N5O
Molecular WeightFinasteride: 372.55 g/mol / Minoxidil: 209.25 g/mol
Compound Class5α-reductase inhibitor + potassium channel opener / vasodilatory research compound
PurityResearch-grade purity
InChIKeyFinasteride: DBEPLOCGEIEOCV-WSBQPABSSA-N / Minoxidil: ZQPPMHVWECSIRJ-UHFFFAOYSA-N
Physicochemical Characteristics
AppearanceClear to slightly opalescent, colorless to faint yellow solution.
Formulation TypeTopical Solution
Delivery SystemSolvent-based topical formulation
Solubility ContextHydroalcoholic multi-solvent carrier architecture utilized to support stable dual-compound dispersion of 0.25% w/v Finasteride and 5% w/v Minoxidil.
Water ContentContains purified water as part of the hydroalcoholic carrier system.
StorageStore tightly closed in a cool, dry, dark environment.
StabilityStability may vary depending on exposure to heat, light, oxygen, and prolonged environmental stress.
Documentation & Analytical Data
Analytical StandardResearch-grade analytical reference
Research ClassificationNon-clinical research formulation
Laboratory StatusResearch-use material
Batch DocumentationInternal batch documentation and formulation records maintained for research traceability purposes.
Documentation AvailabilityCOA / SDS / Batch Records available upon request depending on batch and formulation configuration.
TraceabilityBatch-level internal reference architecture maintained for controlled formulation tracking.
Research Documentation
Formulation Specification

Concentration system: 0.25% w/v Finasteride + 5% w/v Minoxidil

Equivalent concentration: 2.5 mg/mL Finasteride + 50 mg/mL Minoxidil

Total active content: 125 mg Finasteride + 2.5 g Minoxidil per 50 mL

Vehicle system: Ethanol 96% (Ph. Eur.) / Propylene Glycol (Ph. Eur.) / Diethylene Glycol Monoethyl Ether — Transcutol® P (Ph. Eur.) / Purified Water (Ph. Eur.)

Solvent ratio: 45 / 27.5 / 12.5 / 15

Formulation architecture: Hydroalcoholic multi-solvent topical carrier system designed to support compound solubility, formulation consistency, and controlled surface application modeling.

Water content: Purified water included as part of the carrier system.

Formulation complexity: Dual-compound system

Research Context

This dual-compound topical formulation combines Finasteride and Minoxidil for non-clinical research models involving localized androgen pathway interaction, follicular response investigation, carrier-system compatibility, and surface-applied compound behavior.

In topical research contexts, the formulation is evaluated as a solvent-based dual-compound system where localized delivery behavior, compound dispersion, hydroalcoholic carrier compatibility, and formulation consistency are relevant experimental parameters.

Experimental focus is generally directed toward surface-confined delivery architecture, combined compound dispersion behavior, and controlled localized exposure modeling within non-clinical laboratory environments.

This GeneTherica formulation is positioned as a research-grade topical solution for controlled, non-clinical laboratory use. It is not supplied for therapeutic, diagnostic, cosmetic, or human application.

Storage & Handling

Storage range: 15–25°C under controlled room-temperature conditions.

Storage conditions: Store tightly closed in a cool, dry, dark environment.

Light sensitivity: Protect from direct sunlight and UV exposure.

Temperature stability: Avoid freezing and excessive heat exposure.

Air exposure: Minimize prolonged exposure to air.

Closure requirement: Keep container tightly sealed when not in use.

Stability context: Storage conditions are intended to support solvent balance, formulation consistency, and compound stability during controlled non-clinical handling.

Research Use Notice

Supplied exclusively for laboratory research and analytical applications.

Not intended for therapeutic, cosmetic, veterinary, food, household, diagnostic, or human application.

Handling should occur within qualified non-clinical research environments only.

Vehicle System
Multi-Solvent Carrier Architecture
Ethanol 96% Ph. Eur.
Propylene Glycol Ph. Eur.
Transcutol® P Ph. Eur.
Purified Water Ph. Eur.
Solvent Ratio 45 / 27.5 / 12.5 / 15
Research Use Notice
GeneTherica products are supplied for research use only. Products are not medicines, cosmetics, or approved therapeutic agents. Information provided is for technical and research-context identification only and does not constitute medical, clinical, or treatment guidance.
Documentation Availability
COA / SDS / Batch Records
Available upon request depending on batch and formulation configuration.
Research-Grade Quality
Manufactured under defined quality standards for consistent research performance.
Topical Delivery System
Solvent-based formulation designed for localized and targeted research applications.
Transparency
Full documentation and traceability for every research batch.
Secure & Confidential
Your research and inquiries are handled with complete confidentiality.

Overview

Finasteride + Minoxidil is a multi-compound topical research formulation investigated within controlled non-clinical environments involving localized androgen pathway modulation and surface-level delivery system behavior.

Within topical research frameworks, Finasteride is commonly examined for its interaction with localized 5α-reductase-related signaling pathways, while Minoxidil is evaluated in experimental models involving localized tissue-response dynamics and surface-confined formulation exposure.

Experimental focus is generally directed toward localized biochemical interaction behavior, compound compatibility within hydroalcoholic carrier systems, and controlled delivery architecture associated with topical research formulations.

Research applications emphasize surface-confined topical carrier systems designed to support formulation consistency, compound dispersion behavior, and localized exposure modeling within controlled laboratory environments.

This formulation is presented as a research-grade topical solution intended exclusively for scientific, analytical, and laboratory-based investigation under appropriately controlled non-clinical handling conditions.

Laboratory liquid surface
Scientific liquid wave
Laboratory glassware
GeneTherica Documentation Infrastructure

Research Documentation & Technical Systems

Documentation architecture associated with the RU58841 topical research system, including batch-level analytical reference, solvent-system infrastructure, physicochemical handling orientation, and controlled safety documentation access.
Research Infrastructure
Technical Documentation Layer
GeneTherica documentation systems are structured around controlled formulation architecture, analytical reference context, solvent-system engineering, and batch-oriented research documentation.
Research Overview →
Physicochemical Orientation
Documentation emphasizes solvent compatibility, evaporation behavior, crystallization prevention, and controlled carrier architecture.
Batch-Level Structure
Technical references may include batch identifiers, analytical specification context, and raw material traceability layers.
Research Context
Documentation infrastructure is intended for controlled non-clinical research orientation and laboratory identification purposes.
Controlled Systems
Access to certain documentation layers may depend on compound configuration, formulation type, and request evaluation.